STRATEGIC
PHARMA
INCORPORATED

Today's Research Tomorrow's Solutions

November 15, 2016

Our Speaker

Jenalee Alexander

Vice President of Marketing

SPI Vice President of Marketing Jenalee Alexander is an expert in communication solutions. Her passion for improving the lives of others emboldened her in pursuit towards a career in the clinical research industry.

STRATEGIC
PHARMA
INCORPORATED

1 | What We Do and Why We Do it

People Matter

At SPI, we focus on people first—ensuring that our research seeks the best outcomes for people suffering with life altering ailments.

STRATEGIC
PHARMA
INCORPORATED

2 | Framing the Opportunities

Few Formal Trials

Less than 100 (98) trials have been run since 1985 targeting the CB1 and CB2 receptors

Broad Potential

Cannabis/Hemp extracts have been reported to treat as many as 87 different disease indications



Many Components

There have been 545 natural components identified in Cannabis, of those, 104 are cannabinoids.

STRATEGIC
PHARMA
INCORPORATED

3 | The SPI Impact

Unlimited Potential

Over 50% of drugs approved in the last 30 years derived from *Natural* Products

- Cannabis extracts have been reported to **87 different disease indications**.
- Strategic Pharma is categorizing **54 disease indications**



Safety in Science

Cannabis and CBD are Safe.

- Clinical studies with CBD have demonstrated compound is well tolerated with low side effects
- No side events have been detected with CBD doses as high as 100 mg/kg



Prescription Drugs

A recent study showed drastic reduction in prescription medicines in states with legal medical marijuana such as Gabopentin.

- Strategic Pharma is able to show a more effective method of treating chronic pain



Over the Counter Pain Relief

CBD 10x more effective than Ibuprofien

- Asparin causes bleeding in the stomach which distracts body from pain it is experiencing elsewhere
- CBD does not cause bleeding



Replacing Opioids

It is likely that CB1 receptor agonists (Cannabis) will prove to be more effective than opioids in suppressing pain caused by nerve damage (neuropathic pain).

- 5x less morphine and retain effectiveness over a longer period of time



STRATEGIC
PHARMA
INCORPORATED

3 | How We Can Do What We Do

Unprecedented Licensure

Our DEA Schedule 1 License, MED Occupational License, and Medical Cannabis Testing License allow us to find the optimum pure doses of THC and CBD.

As a result, SPI can fully test all strains and extract compositions available in the highest quality organic hemp and marijuana.

Optimized Facilities

Our facilities are custom built for optimal neuroscience research. We can compare our research results side by side with products currently on the market through a clinically relevant process.



Quality Control

Each batch tested for :

- Cannabinoid content, Heavy Metals, residual solvent, pesticides, fertilizers and microbials
- No raw material enters manufacturing until passes tests
- Tablets verified through GMP manufacture to be at least 25 mg CBD

Efficient Focus

Our focus on the central and peripheral nervous systems allows us to determine the best courses of action without wasting time on distractions.

Clinically Relevant Testing

We use clinically relevant, validated tests to aid in creating precisely-defined and designed products that target a variety of ailments while emphasizing better results.

Comprehensive Research Analytics

Our comprehensive research analytics meet the high standards used and required in the pharmaceutical industry. We can provide in-depth information to clients and the people they help.

- Matching Strain with Indication
- Identifying Relevant Biomarkers
- Connecting Biomarkers and Strain

Expedited Time to Market

Our efficiency, team of experts, and capacities enable us to get products to market quickly. On average, we have the ability to move products forward in as little as nine months vs. the traditional standard of 6–10 years.

Our Trajectory

SPI is poised to create solutions for ailments of the course of the next year:

- Pain - Oct. 2016
- Epilepsy - Dec. 2016
- Anxiety - Feb. 2017
- TBI/CTE - May 2017
- Sleep - July 2017
- Depression - Aug. 2017
- Psychosis - Sept. 2017
- PTSD -Dec. 2017



SPI Leadership

Ours is a team of unique experts elevating cannabis with extensive experience in:

- Executive leadership
- Entrepreneurialism
- Leading public and private equity initiatives
- Pre-clinical and early stage clinical development
- Hands-on drug development
- Clinical research
- Clinical operations
- Laboratory operations
- In-vivo neuropharmacology
- Pain and drugs of abuse
- Phase work management

Christopher Meredith, EdD
CEO/Founder

Dan Menard, PhD, PsyT
Executive Vice President of Research & Development

Kirsten Raehal, PhD
Senior Scientist

Andy Cooke, PhD
Senior Director of Scientific Operations

STRATEGIC
PHARMA
INCORPORATED

4 | Questions?

Thank You

November 15, 2016